|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 April 2001, Vol. 97, No. 7, pp. 1925-1928
CHEMOKINES
Polymorphism in the fractalkine receptor CX3CR1 as a
genetic risk factor for coronary artery disease
Didier Moatti,
Sophie Faure,
Frédéric Fumeron,
Mohamed El Walid Amara,
Patrick Seknadji,
David H. McDermott,
Patrice Debré,
Marie Claude Aumont,
Philip M. Murphy,
Dominique de
Prost, and
Christophe Combadière
From INSERM U479, Faculté Bichat, Paris, France;
CNRS UMR 7627, Laboratoire d'Immunologie Cellulaire et Tissulaire,
Hôpital Pitié-Salpêtrière, Paris, France;
Service de Nutrition Humaine, Faculté Bichat, Paris, France;
Service de Cardiologie, CHU Bichat, Paris, France; Laboratory of Host
Defenses, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD, USA; and Service
d'Hématologie Biologique et Immunologie, Hôpital Louis
Mourier AP-HP, Colombes, France.
Coronary atherosclerosis is a major cause of death in
industrialized countries. Monocytes, which play a key role in
atherosclerosis, migrate into the vessel wall, presumably guided by
specific chemoattractant and adhesion molecules. A compelling
candidate for this role is the chemokine receptor CX3CR1, which is
expressed on monocytes and acts as either a chemotactic receptor or an
adhesion molecule, depending on whether its ligand, fractalkine, is
presented free or membrane bound. A common variant of CX3CR1 was
recently identified, encoded by the alleles I249 and M280, which form a
common I249M280 haplotype. When CX3CR1
genotypes were analyzed in 151 patients with acute coronary syndromes
and in 249 healthy controls, CX3CR1 I249 heterozygosity was associated
with a markedly reduced risk of acute coronary events, independent of
established acquired coronary risk factors (eg, smoking, diabetes). The
adjusted odds ratio for this allele was 0.43 (95% confidence interval,
0.26-0.72; P = .001). Consistent with this, functional
analysis of peripheral blood mononuclear cells showed that CX3CR1 I249
heterozygosity was associated with a significant decrease in the number
of fractalkine binding sites per cell. The results show that CX3CR1
I249 is an independent genetic risk factor for coronary artery disease
and that CX3CR1 may be involved in the pathogenesis of atherosclerotic disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Zanchi, C. Zoja, M. Morigi, F. Valsecchi, X. Y. Liu, D. Rottoli, M. Locatelli, S. Buelli, A. Pezzotta, P. Mapelli, et al.
Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin
J. Immunol.,
July 15, 2008;
181(2):
1460 - 1469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Saederup, L. Chan, S. A. Lira, and I. F. Charo
Fractalkine Deficiency Markedly Reduces Macrophage Accumulation and Atherosclerotic Lesion Formation in CCR2-/- Mice: Evidence for Independent Chemokine Functions in Atherogenesis
Circulation,
April 1, 2008;
117(13):
1642 - 1648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tuo, C. M. Bojanowski, M. Zhou, D. Shen, R. J. Ross, K. I. Rosenberg, D. J. Cameron, C. Yin, J. A. Kowalak, Z. Zhuang, et al.
Murine Ccl2/Cx3cr1 Deficiency Results in Retinal Lesions Mimicking Human Age-Related Macular Degeneration
Invest. Ophthalmol. Vis. Sci.,
August 1, 2007;
48(8):
3827 - 3836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Barlic and P. M. Murphy
Chemokine regulation of atherosclerosis
J. Leukoc. Biol.,
August 1, 2007;
82(2):
226 - 236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Barlic, Y. Zhang, and P. M. Murphy
Atherogenic Lipids Induce Adhesion of Human Coronary Artery Smooth Muscle Cells to Macrophages by Up-regulating Chemokine CX3CL1 on Smooth Muscle Cells in a TNF{alpha}-NF{kappa}B-dependent Manner
J. Biol. Chem.,
June 29, 2007;
282(26):
19167 - 19176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. PINGIOTTI, P. CIPRIANI, A. MARRELLI, V. LIAKOULI, S. FRATINI, M. PENCO, and R. GIACOMELLI
Surface Expression of Fractalkine Receptor (CX3CR1) on CD4+/CD28 T Cells in RA Patients and Correlation with Atherosclerotic Damage
Ann. N.Y. Acad. Sci.,
June 1, 2007;
1107(1):
32 - 41.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, V. Godot, F. Capel, S. Adnot, S. Eddahibi, M. Mazmanian, E. Fadel, et al.
Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension
Eur. Respir. J.,
May 1, 2007;
29(5):
937 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schafer, C. Schulz, D. Fraccarollo, P. Tas, M. Leutke, M. Eigenthaler, S. Seidl, P. Heider, G. Ertl, S. Massberg, et al.
The CX3C Chemokine Fractalkine Induces Vascular Dysfunction by Generation of Superoxide Anions
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2007;
27(1):
55 - 62.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ancuta, J. Wang, and D. Gabuzda
CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells.
J. Leukoc. Biol.,
November 1, 2006;
80(5):
1156 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Liu, S. Patil, M. Rojas, A. M. Fong, S. S. Smyth, and D. D. Patel
CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2006;
26(9):
2056 - 2062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Barlic, Y. Zhang, J. F. Foley, and P. M. Murphy
Oxidized Lipid-Driven Chemokine Receptor Switch, CCR2 to CX3CR1, Mediates Adhesion of Human Macrophages to Coronary Artery Smooth Muscle Cells Through a Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Pathway
Circulation,
August 22, 2006;
114(8):
807 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Furuichi, J.-L. Gao, and P. M. Murphy
Chemokine Receptor CX3CR1 Regulates Renal Interstitial Fibrosis after Ischemia-Reperfusion Injury
Am. J. Pathol.,
August 1, 2006;
169(2):
372 - 387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Wallace, R. W. Vaughan, E. Kondeatis, R. Mathew, Y. Chen, E. M. Graham, and M. R. Stanford
A CX3CR1 Genotype Associated with Retinal Vasculitis in Patients in the United Kingdom.
Invest. Ophthalmol. Vis. Sci.,
July 1, 2006;
47(7):
2966 - 2970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-O. Moon, W. Kim, M. J. Sung, S. Lee, K. P. Kang, D. H. Kim, S. Y. Lee, J.-N. So, and S. K. Park
Resveratrol Suppresses Tumor Necrosis Factor-{alpha}-Induced Fractalkine Expression in Endothelial Cells
Mol. Pharmacol.,
July 1, 2006;
70(1):
112 - 119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Norata, K. Garlaschelli, M. Ongari, S. Raselli, L. Grigore, and A. L. Catapano
Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness
Stroke,
June 1, 2006;
37(6):
1558 - 1561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Huang, F.-D. Shi, S. Jung, G. C. Pien, J. Wang, T. P. Salazar-Mather, T. T. He, J. T. Weaver, H.-G. Ljunggren, C. A. Biron, et al.
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system
FASEB J,
May 1, 2006;
20(7):
896 - 905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chen, S. R. Green, F. Almazan, and O. Quehenberger
The Amino Terminus and the Third Extracellular Loop of CX3CR1 Contain Determinants Critical for Distinct Receptor Functions
Mol. Pharmacol.,
March 1, 2006;
69(3):
857 - 865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Davis and J. K. Harrison
Proline 326 in the C Terminus of Murine CX3CR1 Prevents G-Protein and Phosphatidylinositol 3-Kinase-Dependent Stimulation of Akt and Extracellular Signal-Regulated Kinase in Chinese Hamster Ovary Cells
J. Pharmacol. Exp. Ther.,
January 1, 2006;
316(1):
356 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Damas, A. Boullier, T. Waehre, C. Smith, W. J. Sandberg, S. Green, P. Aukrust, and O. Quehenberger
Expression of Fractalkine (CX3CL1) and its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2005;
25(12):
2567 - 2572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Gevrey, B. M. Isaac, and D. Cox
Syk Is Required for Monocyte/Macrophage Chemotaxis to CX3CL1 (Fractalkine)
J. Immunol.,
September 15, 2005;
175(6):
3737 - 3745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Quehenberger
Thematic Review Series: The Immune System and Atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis
J. Lipid Res.,
August 1, 2005;
46(8):
1582 - 1590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lavergne, J. Labreuche, M. Daoudi, P. Debre, F. Cambien, P. Deterre, P. Amarenco, C. Combadiere, and on Behalf of the GENIC Investigators
Adverse Associations Between CX3CR1 Polymorphisms and Risk of Cardiovascular or Cerebrovascular Disease
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2005;
25(4):
847 - 853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Hasegawa, S Sato, T Echigo, Y Hamaguchi, M Yasui, and K Takehara
Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis
Ann Rheum Dis,
January 1, 2005;
64(1):
21 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Teupser, S. Pavlides, M. Tan, J.-C. Gutierrez-Ramos, R. Kolbeck, and J. L. Breslow
Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root
PNAS,
December 21, 2004;
101(51):
17795 - 17800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Davis, V. Zujovic, and J. K. Harrison
Viral Macrophage Inflammatory Protein-II and Fractalkine (CX3CL1) Chimeras Identify Molecular Determinants of Affinity, Efficacy, and Selectivity at CX3CR1
Mol. Pharmacol.,
December 1, 2004;
66(6):
1431 - 1439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Charo and M. B. Taubman
Chemokines in the Pathogenesis of Vascular Disease
Circ. Res.,
October 29, 2004;
95(9):
858 - 866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lavergne, C. Combadiere, M. Iga, A. Boissonnas, O. Bonduelle, M. Maho, P. Debre, and B. Combadiere
Intratumoral CC Chemokine Ligand 5 Overexpression Delays Tumor Growth and Increases Tumor Cell Infiltration
J. Immunol.,
September 15, 2004;
173(6):
3755 - 3762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ghilardi, M. L. Biondi, O. Turri, E. Guagnellini, and R. Scorza
Internal Carotid Artery Occlusive Disease and Polymorphisms of Fractalkine Receptor CX3CR1: A Genetic Risk Factor
Stroke,
June 1, 2004;
35(6):
1276 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Daoudi, E. Lavergne, A. Garin, N. Tarantino, P. Debre, F. Pincet, C. Combadiere, and P. Deterre
Enhanced Adhesive Capacities of the Naturally Occurring Ile249-Met280 Variant of the Chemokine Receptor CX3CR1
J. Biol. Chem.,
May 7, 2004;
279(19):
19649 - 19657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y. Ahn, C.-H. Cho, K.-G. Park, H. J. Lee, S. Lee, S. K. Park, I.-K. Lee, and G. Y. Koh
Tumor Necrosis Factor-{alpha} Induces Fractalkine Expression Preferentially in Arterial Endothelial Cells and Mithramycin A Suppresses TNF-{alpha}-Induced Fractalkine Expression
Am. J. Pathol.,
May 1, 2004;
164(5):
1663 - 1672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Umehara, E. T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and T. Imai
Fractalkine in Vascular Biology: From Basic Research to Clinical Disease
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2004;
24(1):
34 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Lucas, C. Bursill, T. J. Guzik, J. Sadowski, K. M. Channon, and D. R. Greaves
Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX3CR1 and Undergo Chemotaxis to the CX3C Chemokine Fractalkine (CX3CL1)
Circulation,
November 18, 2003;
108(20):
2498 - 2504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Grimm, R. Newman, Z. Hassim, N. Cuan, S. J. Connor, Y. Le, J. M. Wang, J. J. Oppenheim, and A. R. Lloyd
Cutting Edge: Vasoactive Intestinal Peptide Acts as a Potent Suppressor of Inflammation In Vivo by Trans-Deactivating Chemokine Receptors
J. Immunol.,
November 15, 2003;
171(10):
4990 - 4994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Garin, N. Tarantino, S. Faure, M. Daoudi, C. Lecureuil, A. Bourdais, P. Debre, P. Deterre, and C. Combadiere
Two Novel Fully Functional Isoforms of CX3CR1 Are Potent HIV Coreceptors
J. Immunol.,
November 15, 2003;
171(10):
5305 - 5312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Barlic, J. M. Sechler, and P. M. Murphy
IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1
Blood,
November 15, 2003;
102(10):
3494 - 3503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lavergne, B. Combadiere, O. Bonduelle, M. Iga, J.-L. Gao, M. Maho, A. Boissonnas, P. M. Murphy, P. Debre, and C. Combadiere
Fractalkine Mediates Natural Killer-Dependent Antitumor Responses in Vivo
Cancer Res.,
November 1, 2003;
63(21):
7468 - 7474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hundhausen, D. Misztela, T. A. Berkhout, N. Broadway, P. Saftig, K. Reiss, D. Hartmann, F. Fahrenholz, R. Postina, V. Matthews, et al.
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion
Blood,
August 15, 2003;
102(4):
1186 - 1195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dorfmuller, F. Perros, K. Balabanian, and M. Humbert
Inflammation in pulmonary arterial hypertension
Eur. Respir. J.,
August 1, 2003;
22(2):
358 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. DeVries, H. Cao, J. Wang, L. Xu, A. A. Kelvin, L. Ran, L. A. Chau, J. Madrenas, R. A. Hegele, and D. J. Kelvin
Genomic Organization and Evolution of the CX3CR1/CCR8 Chemokine Receptor Locus
J. Biol. Chem.,
March 28, 2003;
278(14):
11985 - 11994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Combadiere, S. Potteaux, J.-L. Gao, B. Esposito, S. Casanova, E. J. Lee, P. Debre, A. Tedgui, P. M. Murphy, and Z. Mallat
Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice
Circulation,
February 25, 2003;
107(7):
1009 - 1016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nishimura, H. Umehara, T. Nakayama, O. Yoneda, K. Hieshima, M. Kakizaki, N. Dohmae, O. Yoshie, and T. Imai
Dual Functions of Fractalkine/CX3C Ligand 1 in Trafficking of Perforin+/Granzyme B+ Cytotoxic Effector Lymphocytes That Are Defined by CX3CR1 Expression
J. Immunol.,
June 15, 2002;
168(12):
6173 - 6180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Balabanian, A. Foussat, P. Dorfmuller, I. Durand-Gasselin, F. Capel, L. Bouche | |
